Following events at the ADA Scientific Sessions in June, a number of concerns raised regarding the ADA's professional section remain unresolved. As a result, a boycott of ADA activities has been initiated by leading figures in diabetes research. The text below includes relevant hyperlinks with further information. Those who wish to review the petition and consider whether to sign it may do so at the links provided. This information is being shared for member awareness.

Stanford Medicine endocrinologist Sun H. Kim, MD, MS, and bariatric surgeon Dan Azagury, MD, FACS, break down how GLP-1 medications work, who may benefit, and why they're not a one-size-fits-all solution. [Watch the video →]. Read full Article here.

SDRC member Anna Gloyn and others lead efforts mapping diabetes risk to pancreatic islet cell heterogeneity and genes that could drive variation in blood sugar regulation.

A decade-long study finds that roughly 1 in 10 people carry genetic variants that may blunt the blood sugar-lowering effects of widely used diabetes medications — raising new questions about precision medicine in diabetes care. Read more...

SDRC Investigator Dr. Jonathan Long's latest research reveals how pTOS — a metabolite that surges dramatically in snake blood after a meal — may offer a novel approach to appetite regulation with implications for diabetes care.

If you’ve ever wondered what happens inside a research lab — and why it matters — this is a look behind the scenes. In Walk with Me, faculty including SDRC members C. Bertozzi, J. Wu and SK Kim talk about the questions guiding their work and the impact they hope to achieve.

Researchers discover how erythropoietin (EPO) signaling in dendritic cells (cDC1s) regulates immune tolerance, offering new pathways for treating diseases like diabetes and other autoimmune conditions.

A novel transplantation strategy resets the immune system and protects replacement islet cells, offering a path to cure Type 1 diabetes.